globenewswire news

Virbac : Half-Year report 2026

2026-09-17T18:00:00Z

Please find attached Virbac half-year report 2026

Attachment

Half-Yearly Financial Report_2026

Articles

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

2026-09-17T21:16:26Z

PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical...

Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)

2026-09-17T21:00:00Z

LOUISVILLE, Ky., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah™ (camizestrant), which is indicated...

NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER

2026-09-17T20:57:00Z

Filing highlights commercial deployments, strengthened capital position and growing opportunity for rapidly deployable power infrastructure

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

2026-09-17T20:15:00Z

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-09-17T20:05:00Z

ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors.

Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

2026-09-17T20:05:00Z

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common...

Vireo Growth Inc. Announces Issuance of Shares in Connection with Altmore Settlement

2026-09-17T20:05:00Z

MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform today announced that, in...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-09-17T20:05:00Z

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today...

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

2026-09-17T20:03:02Z

September 17, 2026 – 22:01PM CET

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

2026-09-17T20:01:00Z

VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-09-17T20:00:00Z

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of...

MAPS Attends Historic FDA Hearing on Psychedelics

2026-09-17T19:55:52Z

WASHINGTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The FDA's September 14 hearing marked one of the most consequential regulatory moments for psychedelic-assisted therapy to date. The Multidisciplinary Association for Psychedelic...

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

2026-09-17T19:48:27Z

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A

AVAVA Announces $45 Million Financing Led by Catalio Capital Management to Accelerate Next Phase of Growth

2026-09-17T19:24:18Z

$30 Million Equity Financing and $15 Million Debt Facility Support Continued Commercial Expansion, Innovation and Global Growth

FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

2026-09-17T19:19:55Z

Innovative gene therapy offers a new option for children with a rare, progressive neurodevelopmental disease

Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases

2026-09-17T18:30:00Z

Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech’s US research presence...

Virbac : Public release of the Half-Year Financial Report at 30 June 2026

2026-09-17T18:00:00Z

Virbac : Public release of the Half-Year Financial Report at 30 June 2026

Virbac : Half-Year report 2026

2026-09-17T18:00:00Z

Please find attached Virbac half-year report 2026

Ultrahuman Launches HealthEx PowerPlug to Combine Medical Records with Continuous Ultrahuman Ring Data for Always-on Health Awareness

2026-09-17T17:49:06Z

HealthEx PowerPlug for Ultrahuman Ring enables members to catch missed follow-ups and see their medical records alongside their biomarkers

PracticeLink Opens Fall 2026 First Practice Fund Applications

2026-09-17T15:56:06Z

$2,500 awards support aspiring physicians and advanced practice providers on their journey from training to practice

VIRBAC: A robust adjusted EBIT margin² of 18.8%, driven by solid organic revenue growth of 7.4%

2026-09-17T15:45:00Z

1Change at constant exchange rates and scope corresponds to organic sales growth, excluding exchange rate variations by calculating the indicator for the current and prior periods using identical exchange rates...